Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Blood. 2004 May 1;103(9):3278-81. Epub 2004 Jan 15.

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Author information

  • 1Department of Pathology, Ohio State University, Columbus, OH 43210, USA.

Abstract

The presence of p53 mutation or deletion predicts for poor response to conventional therapy in chronic lymphocytic leukemia (CLL). We sought to determine whether the humanized anti-CD52 antibody alemtuzumab was effective in this patient group. Thirty-six patients with fludarabine-refractory CLL were treated with alemtuzumab, 15 (42%) of whom had p53 mutations or deletions. Clinical responses in patients with p53 mutations, deletions, or both were noted in 6 (40%) of 15 versus 4 (19%) of 21 of patients without. The median response duration for this subset of patients was 8 months (range, 3-17 months). These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions.

PMID:
14726385
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk